

Advances in Eyelid Lesion Management and Lacrimal Procedures for Optometrists




1

No financial disclosures





2








3 6




























14 1






15 18







HIDROCYSTOMA





20






21 24












26 2





27 30












32







33 36













































50 53







51 54





















Morbidity and Mortality • 5-year survival rate is 50-90% • Higher mortality rate in cases with metastasis (up to 50%!) Significant due to aggressive nature • Local tissue damage Vision impairment Metastasis





62 65






63 66


























74 7






75 78













80 8







81 84













86







87 90











References